Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Alison Oliveto

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPSY Psychiatry, College of Medicine
Address441 Psychiatric Research Institute
4224 Shuffield Dr.
Mail Slot # 843
Little Rock AR 72205
Phone501-526-8441
vCardDownload vCard
    Other Roles
    Member. College of Medicine Promotion and Tenure Committee
    Interviewer. College of Medicine medical student applicants.

    Collapse Overview 
    Collapse overview
    Historically, my career aims have been to improve upon treatments/ treatment access for substance use disorder as well as generally facilitate research in addiction and beyond. As a trained behavioral pharmacologist, I have had continuous NIH funding since 1993 conducting translational research in addiction, including human laboratory and clinical trials, with a focus on psychostimulant and/or opioid use disorders. In 1996 during my tenure at Yale School of Medicine, I established and directed the Outpatient Treatment Research Program at the West Haven CT Veterans Administration Healthcare System (VAHCS) that administratively involved three institutions (Yale, VAHCS, APT Foundation) to ensure the successful conduct of several medications development human laboratory and clinical trials. In 1998 I became Scientific Director of the NIDA P50 medications development center (T. Kosten, PI) and was responsible for coordinating the mentoring of physician scientists and fellows, overseeing research staff, and consolidating resources to maximize research productivity. When I accepted a faculty position at UAMS in 2004, I moved my research and established an addiction research program in the department of Psychiatry and became Vice Chair for Research in Psychiatry at UAMS. I have been responsible for intramural and extramural grant funding, overseeing the career development of clinician scientists, and establishing a research track for Psychiatry residents. I served in several leadership roles on campus, including in our CTSA-funded Translational Research Institute from 2014-2017. I directed the UAMS CTSA-supported Clinical Trials Unit, transforming culture and processes to maximize efficient, regulatory-compliant and rigorous conduct of multi-site trials. I became Director of Psychiatry's Center for Addiction Research in 2016 and have focused on strategic recruitment of addiction scientists as well as developing synergy among CAR/UAMS faculty. In 2020, I became the UAMS site principal investigator in the NIDA Clinical Trials Network Big/SouthWest Node and am awaiting funding on a NIDA CTN multi-site trial. Meanwhile, my focus has shifted to include drug prevention strategies and am currently leading the Arkansas State Epidemiological Outcomes Workgroup in partnership with state agencies, gathering, analyzing and disseminating trends in substance abuse and related outcomes in order to inform prevention efforts across the state.


    Collapse Affiliation 
    Collapse member of
    Fellow, College on Problems of Drug Dependence
    Member. Academic Consortium for Integrative Medicine and Health
    Member. Society for Scientific Exploration

    Collapse Biography 
    Collapse Leadership and Administrative Roles
    Director. Center for Addiction Research, UAMS Department of Psychiatry

    Vice Chair for Research. UAMS Department of Psychiatry and Behavioral Sciences

    Research Director. UAMS Substance Abuse Treatment Clinic/Center for Addiction Services and Treatment

    Team Leader. Arkansas Statewide Epidemiological Outcomes Workgroup

    Member. Steering Committee/Executive Council, Department of Psychiatry and Behavioral Sciences/Psychiatric Research Institute

    Collapse education and training
    St. Lawrence University, Canton, NYB.S.05/1983Chemistry/Psychology
    Univ of North Carolina, Chapel Hill, NCPhD01/1989Exper Psychology/Behav Pharmacology
    Univ of Vermont, Burlington, VTPost-doc09/1991Human Behavioral Pharmacology
    Collapse awards and honors
    1979 - 1983President's Scholar, St. Lawrence University
    1982Psi Chi, Psychology Honorary, St. Lawrence University
    1983N.I.M.H. Predoctoral Research Trainee. Department of Psychology, Univ. of North Carolina - Chapel Hill
    1986 - 1988N.I.D.A. Predoctoral Research Fellow, Univ of North Carolina - Chapel Hill
    1989Travel Award to attend CPDD Meeting, NIDA
    1989Travel Award to attend APA Meeting, American Psychological Assoc
    1990Travel Award to Attend CPDD Meeting, College on Problems of Drug Dependence
    2008Distinguished Alumni Award, Department of Psychology, Univ of North Carolina - Chapel Hill
    2009Fellow, College on Problems of Drug Dependence
    2017 - 2020Certified Clinical Research Professional, Society of Clinical Research Associates
    2019AACAP Outstanding Mentor Award, NIDA

    Collapse Research 
    Collapse research activities and funding
    TI083287-01     (Motley-Bledsoe, Deborah)Apr 1, 2021 - Sep 30, 2022
    SAMHSA - Pass Through Arkansas Department of Human Services
    Medication Assisted Treatment for Opioid Use Disorders among Rural and Uninsured or Underinsured Arkansans
    Role Description: Site Principal Investigator: Michael Mancino, MD To establish and expand medication assisted treatment (MAT) services for opioid use disorders (OUD) within the state by compensating facilities across the state to provide MAT to uninsured and underinsured patients with OUD. Role: Evaluator
    Role: Other Professional

    B08 TI083061     (Barnes, Tenesha)Oct 1, 2020 - Sep 30, 2022
    SAMHSA - Pass Through Arkansas Department of Human Services
    Substance Abuse Bock Grant
    Role Description: The aims of this subcontract from the Arkansas Department of Human Services Division on Aging and Adult Behavioral Health Services and the University of Arkansas at Little Rock School of Social Work/MidSOUTH are to compile, harmonize, analyze and disseminate substance use and substance use-related data among young adults, working closely with state agencies and other stakeholders, in order to guide prevention efforts for this age group in the state of Arkansas. Role: Project Team Leader
    Role: Other Professional

    UG1DA020024     (OLIVETO, ALISON)Jun 1, 2020 - Feb 28, 2025
    NIH/Nat. Inst. on Drug Abuse - Pass Through: University of Texas Southwestern Medical Center - Dallas
    Clinical Trials Network: The Big South/West Node
    Role: Principal Investigator

    SP080990     (Barnes, Tenesha)Oct 1, 2019 - Sep 30, 2023
    SAMHSA - Pass Through Arkansas Department of Human Services
    Partnership for Success: Statewide Epidemiological Outcomes Workgroup for Arkansas
    Role Description: The aims of this subcontract from the Arkansas Department of Human Services Division on Aging and Adult Behavioral Health Services and the University of Arkansas MidSOUTH are to compile, harmonize, analyze and disseminate substance use and substance use-related data among youth and adults, working closely with state agencies and other stakeholders, in order to guide prevention efforts in the state of Arkansas. Role: SEOW Team Leader
    Role: Other Professional

    R01DA048948     (ADDICOTT, MERIDETH A)Aug 15, 2019 - May 31, 2024
    NIH
    Distress Tolerance and Smoking Cessation
    Role: Co-Investigator

    UL1TR003107     (JAMES, LAURA P)Jul 1, 2019 - Jun 30, 2024
    NIH
    Expanding Translational Research in Arkansas
    Role: Co-Investigator

    UAMS Internal Funding     (Addicott, Merideth)Jan 15, 2019 - Oct 31, 2021
    UAMS Center for the Study of Tobacco
    The Effects of Ketamine on Tobacco Use
    Role Description: The overarching aim of this project is to obtain preliminary data on the safety and impact of ketamine on tobacco craving and use in recently abstinent smokers.
    Role: Co-Investigator

    UAMS/TRI Internal Pilot Funds     (Oliveto, Alison)Jan 14, 2019 - Apr 30, 2020
    UAMS/Translational Research Institute
    Gamified Intervention to Prevent Adolescent Opioid Misuse
    Role Description: The overarching goal of this project is to develop a prototype refusal skill gamified opioid misuse prevention module that can be delivered via several platforms (e.g., smartphone, tablet, computer) and determining its initial acceptability and developmental appropriateness in grade-based cohorts of 8th and 11th graders.
    Role: Principal Investigator

    UAMS Internal Funding     (Larson-Prior, Linda)Jan 14, 2019 - Jan 31, 2020
    UAMS/Translational Research Institute
    The impact of buprenorphine on sleep, mood and cognition in opioid use disorder patients participating in a medication assisted treatment program
    Role Description: The overarching goal of this project is to determine whether severity of baseline sleep disruption impacts treatment retention and treatment phase progression; sleep normalizes over a 6 month treatment period; and whether sleep normalization reduces mood and cognitive dysfunction in a population of patients who are being treated with buprenorphine as part of medication assisted treatment for opioid use disorder.
    Role: Co-Investigator

    R21DA045246     (WRIGHT, PATRICIA B)Sep 30, 2018 - Aug 31, 2021
    NIH
    Improving Treatment Strategies for Prescription Opioid Use Disorder- Resubmission
    Role: Co-Investigator

    CFDA 93.788     (Motley-Bledsoe, Deborah)Dec 15, 2017 - Sep 30, 2020
    SAMHSA - Pass Through Arkansas Department of Human Services
    Expanding Access to Medication Assisted Treatment Across the State of Arkansas
    Role Description: This project proposes to increase the number of providers that are waivered providers for buprenorphine and also seeks to increase support for providers engaged in MAT utilizing traditional telemedicine support as well as a Project ECHO approach to enhance the independence of MAT clinicians. Site Principal Investigator: Michael Mancino, MD/Project Principal Investigator: Michael Wilson, MD The aims of this project are to 1) expand distribution of Narcan rescue medication to those at high risk for opioid overdose as well as those who know of those at risk for opioid overdose and 2) facilitate transition of ED patients presenting to the ED with opioid use disorder to medication assisted treatment by inducting patients on buprenorphine and transferring them to a local substance abuse treatment clinic for longer-term care.
    Role: Co-Investigator

    U54TR001629     (JAMES, LAURA P)Sep 26, 2017 - Aug 31, 2019
    NIH
    Expanding Translational Research in Arkansas
    Role: Co-Investigator

    R01DA039088     (OLIVETO, ALISON)Jul 15, 2015 - May 31, 2021
    NIH
    Improving Treatment Outcomes for Prescription Opioid Dependence
    Role: Principal Investigator

    R01DA039088     (OLIVETO, ALISON)Jul 15, 2015 - May 31, 2021
    NIH
    Improving Treatment Outcomes for Prescription Opioid Dependence
    Role: Principal Investigator

    R21DA034824     (MANCINO, MICHAEL J)Aug 1, 2013 - Jul 31, 2016
    NIH
    Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence
    Role: Co-Investigator

    R21DA035325     (OLIVETO, ALISON)Apr 15, 2013 - Mar 31, 2016
    NIH/Nat. Inst. on Drug Abuse
    Improving Buprenorphine Detoxification Outcomes with Isradipine
    Role: Principal Investigator

    R21DA035325     (OLIVETO, ALISON)Apr 15, 2013 - Mar 31, 2016
    NIH
    Improving Buprenorphine Detoxification Outcomes with Isradipine
    Role: Principal Investigator

    R01AA016917     (OLIVETO, ALISON)Jun 5, 2012 - Jul 31, 2012
    NIH/Nat. Inst. on Alcohol Abuse & Alcoholism - Pass Through: Dartmouth College
    Family Bases Contingency Management for Adolescent Alcohol Abuse
    Role: Principal Investigator

    R21DA031837     (OLIVETO, ALISON)May 1, 2012 - Aug 31, 2015
    NIH/Nat. Inst. on Drug Abuse
    Impact of CYP2D6 Phenotype on Response to Methamphetamine in Humans
    Role: Principal Investigator

    R21DA031837     (OLIVETO, ALISON)May 1, 2012 - Aug 31, 2015
    NIH
    Impact CYP2D6 Phenotype on Response to Methamphetamine in Humans
    Role: Principal Investigator

    R21DA029842     (OLIVETO, ALISON)Aug 1, 2011 - Jun 30, 2015
    NIH
    Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
    Role: Principal Investigator

    R21DA029842     (OLIVETO, ALISON)Aug 1, 2011 - Jun 30, 2015
    NIH
    Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
    Role: Principal Investigator

    R01DA026916     (GENTRY, WILLIAM)Sep 1, 2009 - Jul 31, 2013
    NIH/Nat. Inst. on Drug Abuse
    Monoamine Antagonist Therapies for Methamphetamine Abuse
    Role: Co-Investigator

    P20RR020146     (GARCIA-RILL, EDGAR E.)Sep 16, 2004 - Apr 30, 2014
    NIH
    Center for Translational Neuroscience
    Role: Co-Investigator

    R01DA014388     (OLIVETO, ALISON)Jul 9, 2001 - Jun 30, 2006
    NIH/Nat. Inst. on Drug Abuse
    Behavioral Effects of GHB in Healthy Volunteers
    Role: Principal Investigator

    R01DA013441     (OLIVETO, ALISON)Jul 1, 2000 - Dec 31, 2012
    NIH
    Disulfiram for Cocaine Abuse in Metadone - Patients
    Role: Principal Investigator

    R01DA013441     (OLIVETO, ALISON)Jul 1, 2000 - Dec 31, 2012
    NIH/Nat. Inst. on Drug Abuse
    Disulfiram for Cocaine Abuse in Methadone-Maintained Patients
    Role: Principal Investigator

    R01DA010017     (OLIVETO, ALISON)Sep 30, 1997 - Nov 30, 2012
    NIH/Nat. Inst. on Drug Abuse
    Opioid Antagonist Discrimination: A Model of Withdrawal
    Role: Principal Investigator

    R01DA010017     (OLIVETO, ALISON)Sep 30, 1997 - Nov 30, 2012
    NIH
    Opioid Antagonist Discrimination: A Model of Withdrawal
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse additional bibliographic sources
    The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Phillips SJ, Oliveto A, Mancino MJ, Hendrickson HP. Development and validation of a rapid liquid chromatography/tandem mass spectrometry method to quantitate gabapentin and buprenorphine in human serum. Rapid Commun Mass Spectrom. 2021 Jul 31; 35(14):e9104. PMID: 33860565.
      View in: PubMed
    2. Allison Schneider BS, Samuel Mullinax BA, Oliveto AH, Acheson A, Wilson MP. In reply: Bias risk in systematic reviews. Am J Emerg Med. 2021 07; 45:600-601. PMID: 33390297.
      View in: PubMed
    3. Kumar N, Mancino MJ, Thostenson JD, McGaugh J, Oliveto AH. Feasibility and Preliminary Efficacy of Isradipine During Outpatient Buprenorphine Stabilization and Detoxification: A Pilot Randomized, Placebo-Controlled Trial. Subst Abuse. 2020; 14:1178221820970926. PMID: 33281447.
      View in: PubMed
    4. Schneider A, Mullinax S, Hall N, Acheson A, Oliveto AH, Wilson MP. Intramuscular medication for treatment of agitation in the emergency department: A systematic review of controlled trials. Am J Emerg Med. 2021 08; 46:193-199. PMID: 33071100.
      View in: PubMed
    5. Wilson MP, Cucciare MA, Porter A, Chalmers CE, Mullinax S, Mancino M, Oliveto AH. The utility of a statewide prescription drug-monitoring database vs the Current Opioid Misuse Measure for identifying drug-aberrant behaviors in emergency department patients already on opioids. Am J Emerg Med. 2020 03; 38(3):503-507. PMID: 31221474.
      View in: PubMed
    6. Chalmers CE, Mullinax S, Brennan J, Vilke GM, Oliveto AH, Wilson MP. Screening Tools Validated in the Outpatient Pain Management Setting Poorly Predict Opioid Misuse in the Emergency Department: A Pilot Study. J Emerg Med. 2019 Jun; 56(6):601-610. PMID: 31043338.
      View in: PubMed
    7. Nahata R, Mancino MJ, Thostenson J, Oliveto AH. Survey of Treatment Preferences for Opioid Use Disorder. Jacobs J Addict Ther. 2018; 5(3). PMID: 31131330.
      View in: PubMed
    8. Bashiri M, Mancino MJ, Stanick VA, Thostenson J, Kosten TR, Oliveto AH. Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: A retrospective analysis of two clinical trials. Am J Addict. 2017 Dec; 26(8):807-814. PMID: 29115703.
      View in: PubMed
    9. Bashiri M, Greenfield LJ, Oliveto A. Telemedicine Interest for Routine Follow-Up Care Among Neurology Patients in Arkansas. Telemed J E Health. 2016 06; 22(6):514-8. PMID: 26684500.
      View in: PubMed
    10. Mancino MJ, McGaugh J, Chopra MP, Guise JB, Cargile C, Williams DK, Thostenson J, Kosten TR, Sanders N, Oliveto A. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol. 2014 Apr; 34(2):234-9. PMID: 24525654.
      View in: PubMed
    11. Sanders NC, Mancino MJ, Gentry WB, Guise JB, Bickel WK, Thostenson J, Oliveto AH. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol. 2013 Aug; 21(4):294-302. PMID: 23855333.
      View in: PubMed
    12. Atkinson TS, Sanders N, Mancino M, Oliveto A. Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. J Addict Med. 2013 Jul-Aug; 7(4):243-8. PMID: 23648640.
      View in: PubMed
    13. Oliveto A, Mancino M, Sanders N, Cargile C, Benjamin Guise J, Bickel W, Brooks Gentry W. Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure. Eur J Pharmacol. 2013 Sep 05; 715(1-3):424-35. PMID: 23524089.
      View in: PubMed
    14. Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R, Gonsai K, Sofuoglu M, Gonzalez G, Tripathi S, Kosten TR. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction. 2012 Jan; 107(1):131-41. PMID: 21707811.
      View in: PubMed
    15. Mancino MJ, Gentry BW, Feldman Z, Mendelson J, Oliveto A. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse. 2011 Mar; 37(2):131-6. PMID: 21219261.
      View in: PubMed
    16. Oliveto A, Poling J, Mancino MJ, Feldman Z, Cubells JF, Pruzinsky R, Gonsai K, Cargile C, Sofuoglu M, Chopra MP, Gonzalez-Haddad G, Carroll KM, Kosten TR. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend. 2011 Jan 15; 113(2-3):184-91. PMID: 20828943.
      View in: PubMed
    17. Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J. Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol. 2010 Jul; 21(4):332-42. PMID: 20526195.
      View in: PubMed
    18. Mancino MJ, McGaugh J, Feldman Z, Poling J, Oliveto A. Effect of PTSD diagnosis and contingency management procedures on cocaine use in dually cocaine- and opioid-dependent individuals maintained on LAAM: a retrospective analysis. Am J Addict. 2010 Mar-Apr; 19(2):169-77. PMID: 20163389.
      View in: PubMed
    19. Oliveto A, Pruzinsky R, Poling J, Gentry WB, Martell B, Gonsai K, Kosten TR. Behavioral effects of GHB in humans. Behavioural Pharmacology. 2010; 21(4):332-42.
    20. McGaugh J, Mancino MJ, Feldman Z, Chopra MP, Gentry WB, Cargile C, Oliveto A. Open-label pilot study of modafinil for methamphetamine dependence. J Clin Psychopharmacol. 2009 Oct; 29(5):488-91. PMID: 19745650.
      View in: PubMed
    21. Chopra MP, Feldman Z, Mancino MJ, Oliveto A. Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis. Pharmacol Biochem Behav. 2008 Oct; 90(4):787-96. PMID: 18585405.
      View in: PubMed
    22. Chopra M.P, Feldman Z.L, Mancino M.J, Oliveto A. Response to naloxone versus placebo in opioid-dependent humans responding under a naloxone discrimination procedure: influences of sex and opioid maintenance dose. Pharmacology, Biochemistry and Behavior. 2008; 90(4):787-96.
    23. Sofuoglu M, Poling J, Gonzalez G, Gonsai K, Oliveto A, Kosten TR. Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study. Exp Clin Psychopharmacol. 2007 Oct; 15(5):453-60. PMID: 17924779.
      View in: PubMed
    24. Poling J, Pruzinsky R, Kosten TR, Gonsai K, Sofuoglu M, Gonzalez G, Oliveto A. Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients. Am J Addict. 2007 May-Jun; 16(3):187-94. PMID: 17612822.
      View in: PubMed
    25. González G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, Kosten TR. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend. 2007 Feb 23; 87(1):1-9. PMID: 16930857.
      View in: PubMed
    26. Kosten TR, Scanley BE, Tucker KA, Oliveto A, Prince C, Sinha R, Potenza MN, Skudlarski P, Wexler BE. Cue-induced brain activity changes and relapse in cocaine-dependent patients. Neuropsychopharmacology. 2006 Mar; 31(3):644-50. PMID: 16123763.
      View in: PubMed
    27. Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, Martell B, Kosten TR. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006 Feb; 63(2):219-28. PMID: 16461866.
      View in: PubMed
    28. Oliveto A, Poling J, Sevarino KA, Gonsai KR, McCance-Katz EF, Stine SM, Kosten TR. Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug Alcohol Depend. 2005 Aug 01; 79(2):157-65. PMID: 16002025.
      View in: PubMed
    29. Kosten T, Sofuoglu M, Poling J, Gonsai K, Oliveto A. Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response. Am J Addict. 2005 Jan-Feb; 14(1):8-17. PMID: 15804873.
      View in: PubMed
    30. Hughes JR, Oliveto AH, Riggs R, Kenny M, Liguori A, Pillitteri JL, MacLaughlin MA. Concordance of different measures of nicotine dependence: two pilot studies. Addict Behav. 2004 Nov; 29(8):1527-39. PMID: 15451122.
      View in: PubMed
    31. Oliveto A, Poling J, Kosten TR, Gonsai K. Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure. Eur J Pharmacol. 2004 May 03; 491(2-3):157-68. PMID: 15140632.
      View in: PubMed
    32. Gonzalez G, Oliveto A, Kosten TR. Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother. 2004 Apr; 5(4):713-25. PMID: 15102558.
      View in: PubMed
    33. Kosten T, Falcioni J, Oliveto A, Feingold A. Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. Am J Addict. 2004 Mar-Apr; 13(2):191-201. PMID: 15204669.
      View in: PubMed
    34. Kosten T.R, Falcioni J, Oliveto A, Feingold A. Depression predicts poor treatment response with desipramine and methadone or buprenorphine among cocaine and opioid dependent patients. American Journal on the Addictions. 2004; 13(2):191-201.
    35. Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction. 2003 Nov; 98(11):1625-32. PMID: 14616189.
      View in: PubMed
    36. Gonzalez G, Feingold A, Oliveto A, Gonsai K, Kosten TR. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am J Drug Alcohol Abuse. 2003 Aug; 29(3):497-514. PMID: 14510037.
      View in: PubMed
    37. Oliveto A, Benios T, Gonsai K, Feingold A, Poling J, Kosten TR. D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure. Exp Clin Psychopharmacol. 2003 Aug; 11(3):237-46. PMID: 12940503.
      View in: PubMed
    38. Sofuoglu M, Singha A, Kosten TR, McCance-Katz FE, Petrakis I, Oliveto A. Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacol Biochem Behav. 2003 Jul; 75(4):801-8. PMID: 12957222.
      View in: PubMed
    39. Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003 Jun 05; 70(3):315-25. PMID: 12757969.
      View in: PubMed
    40. Kosten T, Poling J, Oliveto A. Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients. Addiction. 2003 May; 98(5):665-71. PMID: 12751984.
      View in: PubMed
    41. Kosten TR, Oliveto A, Sevarino KA, Gonsai K, Feingold A. Ketoconazole increases cocaine and opioid use in methadone maintained patients. Drug Alcohol Depend. 2002 Apr 01; 66(2):173-80. PMID: 11906804.
      View in: PubMed
    42. Feingold A, Oliveto A, Schottenfeld R, Kosten TR. Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers. Am J Addict. 2002; 11(2):111-23. PMID: 12028741.
      View in: PubMed
    43. Gonzalez G, Oliveto A, Kosten TR. Treatment of heroin (diamorphine) addiction: current approaches and future prospects. Drugs. 2002; 62(9):1331-43. PMID: 12076182.
      View in: PubMed
    44. Oliveto A, Sevarino K, McCance-Katz E, Feingold A. Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure. Pharmacol Biochem Behav. 2002 Jan-Feb; 71(1-2):85-96. PMID: 11812511.
      View in: PubMed
    45. Oliveto A.H, Rosen M, Kosten T.A, Hameedi F, Woods S, Kosten T.R. Naloxone discrimination in opioid-dependent humans under a novel-response discrimination procedure. Experimental and Clinical Psychopharmacology. 1998; (6):169-178.
    46. Oliveto A.H, Kosten T. R. New Treatments for Opiate Dependence. Buprenorphine. 1997.
    47. Hughes J.H, Oliveto A.H, Higgins S.T, Bickel W.K, Terry S.Y. Saying vs. doing and other methodological issues in the study of human drug self-administration. Experimental and Clinical Psychopharmacology. 1996; (4):234-238.
    48. Best S.E, Oliveto A.H, Kosten T.R. Opioid Addiction: Recent Advances in Detoxification and Maintenance Therapy. CNS Drugs. 1996; (6):301-304.
    49. Kamien JB, Bickel WK, Oliveto AH, Higgins ST, Hughes JR, Richards AT, Badger GJ. Placebo-effects contribute to differences in the acquisition of drug discrimination by humans: a retrospective analysis. Behav Pharmacol. 1995; 6(2):187 - 194.
    50. Hale K.L, Hughes J.R, Oliveto A.H, Higgins S.T. Caffeine self-administration and subjective effects in adolescents. Experimental and Clinical Psychopharmacology. 1995; (3):364-370.
    51. Hughes, J.R, Oliveto A.H, Bickel W.K, Higgins S.T, Badger G.J. The ability of low doses of caffeine to serve as reinforcers in humans: A replication. Experimental and Clinical Psychopharmacology. 1995; (3):1-6.
    52. Kamien JB, Bickel WK, Oliveto AH, Smith BJ, Higgins ST, Hughes JR, Badger GJ. Triazolam discrimination by humans under a novel response procedure: effects of buspirone and lorazepam. Behav Pharmacol. 1994; 5(3):315 - 325.
    53. Oliveto A.H, Kosten T.R, Schottenfeld R, Ziedonis D, Falcioni J. Cocaine use in buprenorphine- vs methadone-maintained cocaine users. American Journal of Addictions. 1994; (3):43-48.
    54. Oliveto AH, Bickel WK, Hughes JR, Terry SY, Higgins ST, Badger GJ. Pharmacological specificity of the caffeine discriminative stimulus in humans: effects of theophylline, methylphenidate and buspirone. Behav Pharmacol. 1993; 4(3):237 - 246.
    55. McGaugh, J.D., Mancino, M., Gentry, W.B., Chopra, M., Cargile, C., Oliveto A. Open label modafinil for methamphetamine dependence: Safety and tolerability. 70th Annual Meeting of the College on Problems of Drug Dependence.
    56. Oliveto A, Feldman Z, Mancino, M.J. Alcohol dependence diagnosis influences response to disulfiram in dually cocaine- and opioid-dependent humans maintained on methadone. 70th Annual Meeting of the College on Problems of Drug Dependence.
    57. Mancino, M.J., Feldman, Z., Oliveto A. Gender differences in response to disulfiram treatment for cocaine dependence in methadone-stabilized opioid- and cocaine-dependent individuals. 70th Annual Meeting of the College on Problems of Drug Dependence.
    Oliveto's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description